Rapid Readout

SOL-1 phase 3 Readout: Key Efficacy and Safety Outcomes in Neovascular AMD

April 23rd 2026

Dr. Arshad Khanani introduces the SOL-1 phase 3 trial evaluating Axpaxli (OTX-TKI) in treatment-naïve neovascular AMD.

This video series has been produced independently by Ophthalmology Times and supported by Ocular Therapeutix. The following presentation discusses OTX-TKI - an investigational product candidate that has not been approved by the FDA or any other regulatory body

Lorraine Provencher, MD, presenting slides

Harnessing the Power of VR for Visual Field Testing: Results of The NOVA Trial

May 29th 2024

Lorraine Provencher, MD, reviews the NOVA trial which measured and validated the sensitivity of a novel VR-based wearable headset for visual field testing in glaucoma.

Rapid Readout

SOL-1 phase 3 Readout: Key Efficacy and Safety Outcomes in Neovascular AMD

Harnessing the Power of VR for Visual Field Testing: Results of The NOVA Trial

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

Tinlarebant NDA submission completed for Stargardt disease type 1, targeting first approved therapy

FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA)

Study finds mixed real and synthetic eye images enhance ocular AI performance

IOLs: What Every Surgeon Needs to Know | Ep. 2: Enhanced monofocal IOLs

Where eye care leaders go to grow: OWL's annual summit lands in Nashville July 30–31, 2026